Suggested remit: To appraise the clinical and cost effectiveness of upadacitinib within its marketing authorisation for treating moderate to severe atopic dermatitis in people aged 12 and over.
Due to significant capacity challenges NICE has paused the development of the Single Technology Appraisals for [ID3768] abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over, [ID3733] Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over and [ID3734] Tralokinumab for treating moderate to severe atopic dermatitis. All 3 topics will be appraised together as a Multiple Technology Appraisal under [ID3960].
 
Status Suspended
Decision Selected
Process STA 2018
ID number 3733

Project Team

Project lead Shonagh D'Sylva

Email enquiries

Stakeholders

Companies sponsors AbbVie (upadacitinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups British Association of Dermatologists
  British Society for Allergy & Clinical Immunology
  Royal College of Physicians
Professional groups Allergy UK
  National Eczema Society
Comparator companies Accord (azathioprine, methotrexate, mycophenolate mofetil) – not participating
  Advanz Pharma (methotrexate) – not participating
  Aspen (azathioprine) – not participating
  Cipla (methotrexate) – not participating
  Dexcel-Pharma Limited (ciclosporin) – not participating
  Ennogen (alitretion, azathioprine) – not participating
  GlaxoSmithKline (alitretion) – not participating
  Hospira (methotrexate) – not participating
  Medac (methotrexate) – not participating
  Mylan (azathioprine, ciclosporin, mycophenolate mofetil) – not participating
  Nordic Pharma (methotrexate) – not participating
  Novartis Pharmaceuticals (ciclosporin, mycophenolate mofetil)
  Orion Pharma (methotrexate) – not participating
  Pfizer (methotrexate)
  Roche (mycophenolate mofetil) – not participating
  Rosemont Pharmaceuticals (methotrexate) – not participating
  Sandoz (methotrexate, mycophenolate mofetil) – not participating
  Sanofi (dupilumab)
  Santen (ciclosporin) – not participating
  Teva (mycophenolate mofetil) – not participating
  Therakind (methotrexate) – not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
05 August 2021 Due to significant capacity challenges NICE has paused the development of the Single Technology Appraisals for [ID3768] abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over, [ID3733] Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over and [ID3734] Tralokinumab for treating moderate to severe atopic dermatitis. All 3 topics will be appraised together as a Multiple Technology Appraisal under [ID3960].
05 August 2021 Suspended. Due to significant capacity challenges NICE has paused the development of the Single Technology Appraisals for [ID3768] abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over, [ID3733] Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over and [ID3734] Tralokinumab for treating moderate to severe atopic dermatitis. All 3 topics will be appraised together as a Multiple Technology Appraisal under [ID3960].
21 July 2021 Schedule affected by COVID-19. We are continuing to face significant capacity challenges and will be delaying the development of upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]. This topic will now be considered as part of a multiple technology appraisal. We anticipate that it will be considered by the technology appraisal committee in early 2022 .
21 July 2021 We are continuing to face significant capacity challenges and will be delaying the development of upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]. This topic will now be considered as part of a multiple technology appraisal. We anticipate that it will be considered by the technology appraisal committee in early 2022.
10 December 2020 Invitation to participate
10 December 2020 In progress. Final scope issued
16 July 2020 - 13 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual